ettx stock zacks
View detailed financial information, real-time news, videos, quotes and analysis on Entasis Therapeutics Holdings, Inc. (NASDAQ:ETTX). Selected key stats of Entasis Therapeutics Holdings Inc. (ETTX) including 10 year stock price and latest news. 3)* ENTASIS THERAPEUTICS HOLDINGS INC. (Name of Issuer) Common Stock, $0.001 par value (Title … The stock had previously closed at $3.10. Key stats provide selected financials for rapid company overview including revenues, marketcap, P/E ratio, debt and much more. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Revenue: The sum of all revenue fields included for a company's operating activities. Entasis Therapeutics (ETTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. 3) Activist Investment. This price target is based on 7 analysts offering 12 month price targets for Entasis Therapeutics in the last 3 months. Zacks Investment Research lowered shares of Entasis Therapeutics (NASDAQ:ETTX) from a hold rating to a sell rating in a report released on Wednesday morning, Zacks.com reports. According to 7 analysts, the average rating for ETTX stock is "Buy." View real-time stock prices and stock quotes for a full financial overview. Today, you can download 7 Best Stocks for the Next 30 Days. ROAD | Complete Construction Partners Inc. Cl A stock news by MarketWatch. Entasis Therapeutics Holdings Inc. (ETTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy). ETTX has been the topic of several other research reports. Want the latest recommendations from Zacks Investment Research? Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Zacks Investment Research lowered Entasis Therapeutics from a hold rating to a sell rating in a research report on Wednesday, July 8th. According to Zacks, “Entasis Therapeutics Holdings Inc. produces, researches and develops antibacterial therapies and drugs through its subsidiaries. The ratio of debt to operating expenses for Entasis Therapeutics Holdings Inc is higher than it is for about only 5.61% of US stocks. Find real-time ETTX - Entasis Therapeutics Holdings Inc stock quotes, company profile, news and forecasts from CNN Business. Entasis Therapeutics Holdings Inc. ETTX is a clinical-stage biopharmaceutical company. Zacks Investment Research upgraded shares of Entasis Therapeutics (NASDAQ:ETTX) from a strong sell rating to a hold rating in a research report sent to investors on Tuesday, Zacks.com reports. ETTX has been the subject […] The average price target is $6.71, with a high forecast of … Click to get this free report Pacira BioSciences, Inc. (PCRX) : Free Stock Analysis Report Entasis Therapeutics Holdings Inc. (ETTX) : Free Stock Analysis Report To read this article on Zacks.com click here. 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). Several analysts have recently weighed in […] View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Price Target Entasis Therapeutics Holdings Inc. (ETTX) Revenue data is not available for the most recently reported fiscal quarter, ending 2020-09-30. Approximately 638,720 shares changed hands during trading, an increase of 30% from the average daily volume of 492,562 shares. Several other brokerages have also recently issued reports on ETTX. The Zacks Consensus Estimate for its current year earnings has been revised 86.8% downward over the last 30 days. The stock traded as low as $3.26 and last traded at $3.33. ETTX has been the subject of a number of analyst reports. Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) has received a consensus recommendation of “Buy” from the nine analysts that are currently covering the company, MarketBeat Ratings reports. The stock traded as low as $2.58 and last traded at $2.61. 09-01 sec.gov - 1 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)’s stock price dropped 5.7% on Tuesday . Stock Ideas and Recommendations. Zacks Investment Research cut shares of Entasis Therapeutics (NASDAQ:ETTX) from a buy rating to a hold rating in a research note issued to investors on Tuesday morning, Zacks.com reports. Entasis Therapeutics (NASDAQ:ETTX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. Want the latest recommendations from Zacks Investment Research? The stock had previously closed at $3.53. Get the latest Entasis Therapeutics Holdings I (ETTX) stock news and headlines to help you in your trading and investing decisions. Fundamental data provided by Zacks and Morningstar. Entasis Therapeutics Holdings Inc. (ETTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). Today, you can download 7 Best Stocks for the Next 30 Days. Stock screener for investors and traders, financial visualizations. According to Zacks, “Entasis Therapeutics Holdings Inc. produces, researches and develops antibacterial therapies and drugs through its subsidiaries. Entasis Therapeutics Holdings Inc's stock had its IPO on September 26, 2018, making it an older stock than only 4.39% of US equities in our set. Zacks Investment Research lowered shares of Entasis Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 11th. Today's volume of 164,717 shares is on pace to be lower than ETTX's 10-day average volume of 334,599 shares. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Pacira BioSciences, Inc. (PCRX): Free Stock Analysis Report Entasis Therapeutics Holdings Inc. (ETTX): Free Stock Analysis Report To read this article on Zacks.com click here. The average twelve-month price target among analysts that have covered […] 692,781 shares changed hands during mid-day trading, an increase of 153% from the average session volume of 274,018 shares. Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) traded down 8.4% on Monday . The Zacks Consensus Estimate for its current year earnings has been revised 17.7% downward over the last 30 days. The 12-month stock price forecast is 6.50, which is an increase of 129.68% from the latest price. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock … Get daily stock ideas top-performing Wall Street analysts. One analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. Find the latest Entasis Therapeutics Holdings I (ETTX) stock quote, history, news and other vital information to help you with your stock trading and investing. ETTX Description — Entasis Therapeutics Holdings Inc. Entasis Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. ETTX Stock Summary. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The stock had previously closed at $2.85. Credit Suisse Group reiterated an outperform rating and issued a $8.00 price objective on shares of Entasis Therapeutics in a research note on Sunday, June 21st. HC Wainwright dropped their price objective on shares of Entasis Therapeutics from $18.00 to $5.00 and set a buy rating on the stock in a research note on Tuesday, April 14th. ETTX / Entasis Therapeutics Holdings Inc. / Innoviva, Inc. - SCHEDULE 13D/A (AMENDMENT NO.